洛铂联合复方苦参注射液治疗晚期肺癌恶性胸腔积液疗效及机制研究

The efficacy and mechanism of lobaplatin combined with compound matrine injection in the treatment of malignant pleural effusion for patients with advanced lung cancer

目的:评价治疗晚期肺癌恶性胸腔积液使用洛铂联合复方苦参注射液的疗效以及作用机制。方法:将在我院治疗晚期肺癌合并恶性胸腔积液的患者90例作为研究对象,按照随机对照原则均分成三组,其中治疗A组采用纯洛铂治疗方案,治疗B组采用纯顺铂治疗方案,治疗C组采用洛铂联合复方苦参注射液治疗方案,对比三组的治疗效果并检测相关生化指标。结果:治疗C组总有效率比治疗B组高,与治疗A组无差异;三组患者治疗后均比治疗前生化指标有所改善,治疗C组改善程度明显好于治疗A组和B组。结论:对晚期肺癌合并恶性胸腔积液患者采用洛铂联合复方苦参注射液治疗方案,可以明显改善患者的各项生化指标和提高治疗有效率。

Objective：To evaluate the effect and mechanism of advanced lung cancer with malignant pleural effu- sion using lobaplatin combined with compound matrine injection. Methods ：90 patients of advanced lung cancer in our hospital with malignant pleura1 effusion were randomly divided into three groups, the treatment group A adopted pure lobaplatin treatment , group B using pure cisplatin treatment, the group C using lobaplatin combined with compound matrine injection treatment. Biochemical indicators in three groups were detected. Results： The total efficiency of treat- ment group C was higher than group B. The biochemical indicators in three groups of patients after treatment were im- proved,and the group C improved significantly better than the other two groups. Conclusion： Lobaplatin combined with compound matrine injection in treatment of advanced lung cancer patients with malignant pleural effusion, can improve the curative effect and patient, quality of life, significantly improve the biochemical indicators of patients.